Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
Youn H. Kim, Michael Girardi, Madeleine Duvic, et al.
Journal of the American Academy of Dermatology (2010) Vol. 63, Iss. 6, pp. 975-983
Closed Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
Holly E. Barker, James Paget, Aadil Khan, et al.
Nature reviews. Cancer (2015) Vol. 15, Iss. 7, pp. 409-425
Open Access | Times Cited: 1766
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Sarah I. Jawed, Patricia L. Myskowski, Steven Horwitz, et al.
Journal of the American Academy of Dermatology (2014) Vol. 70, Iss. 2, pp. 205.e1-205.e16
Closed Access | Times Cited: 353
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Sarah I. Jawed, Patricia L. Myskowski, Sarah McCue Horwitz, et al.
Journal of the American Academy of Dermatology (2014) Vol. 70, Iss. 2, pp. 223.e1-223.e17
Closed Access | Times Cited: 326
Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer
Julia Scheiermann, Dennis M. Klinman
Vaccine (2014) Vol. 32, Iss. 48, pp. 6377-6389
Open Access | Times Cited: 302
NK cells and ILCs in tumor immunotherapy
Simona Sivori, Daniela Pende, Linda Quatrini, et al.
Molecular Aspects of Medicine (2020) Vol. 80, pp. 100870-100870
Open Access | Times Cited: 191
Antisense oligonucleotides: modifications and clinical trials
Vivek Sharma, Raman K. Sharma, Sunil Kumar Singh
MedChemComm (2014) Vol. 5, Iss. 10, pp. 1454-1471
Closed Access | Times Cited: 189
Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives
Suprabhat Mukherjee, Ritwik Patra, Payam Behzadi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 61
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Youn H. Kim, Dita Gratzinger, Cameron Harrison, et al.
Blood (2011) Vol. 119, Iss. 2, pp. 355-363
Open Access | Times Cited: 206
Trial Watch
Lorenzo Galluzzi, Erika Vacchelli, Alexander Eggermont, et al.
OncoImmunology (2012) Vol. 1, Iss. 5, pp. 699-739
Open Access | Times Cited: 188
CpG Still Rocks! Update on an Accidental Drug
Arthur Μ. Krieg
Nucleic Acid Therapeutics (2012) Vol. 22, Iss. 2, pp. 77-89
Closed Access | Times Cited: 177
Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Huju Chi, Chunman Li, Flora Sha Zhao, et al.
Frontiers in Pharmacology (2017) Vol. 8
Open Access | Times Cited: 161
Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: insight into the molecular mechanisms
Stéphanie Demoulin, Michaël Herfs, Philippe Delvenne, et al.
Journal of Leukocyte Biology (2012) Vol. 93, Iss. 3, pp. 343-352
Closed Access | Times Cited: 146
Evolving Insights in the Pathogenesis and Therapy of Cutaneous T‐cell lymphoma (Mycosis Fungoides and Sezary Syndrome)
Henry K. Wong, Anjali Mishra, Timothy S. Hake, et al.
British Journal of Haematology (2011) Vol. 155, Iss. 2, pp. 150-166
Open Access | Times Cited: 144
Malignant inflammation in cutaneous T‐cell lymphoma—a hostile takeover
Thorbjørn Krejsgaard, Lise M. Lindahl, Nigel P. Mongan, et al.
Seminars in Immunopathology (2016) Vol. 39, Iss. 3, pp. 269-282
Open Access | Times Cited: 129
<p>Toll-Like Receptor 9 Agonists in Cancer</p>
Lilit Karapetyan, Jason J. Luke, Diwakar Davar
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 10039-10061
Open Access | Times Cited: 106
Targeting Toll-Like Receptors for Cancer Therapy
Marc J. Braunstein, John Kucharczyk, Sylvia Adams
Targeted Oncology (2018) Vol. 13, Iss. 5, pp. 583-598
Closed Access | Times Cited: 98
CpG Oligonucleotides as Vaccine Adjuvants
Neslihan Kayraklioglu, Begum Horuluoglu, Dennis M. Klinman
Methods in molecular biology (2020), pp. 51-85
Closed Access | Times Cited: 88
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
Clive S. Zent, Bruce A. Smith, Zuhair K. Ballas, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2011) Vol. 53, Iss. 2, pp. 211-217
Open Access | Times Cited: 86
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside
Burghardt Wittig, Manuel Schmidt, Werner Scheithauer, et al.
Critical Reviews in Oncology/Hematology (2014) Vol. 94, Iss. 1, pp. 31-44
Open Access | Times Cited: 71
An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More
Massimo Vitale, Claudia Cantoni, Mariella Della Chiesa, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 66
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists
Carole Bourquin, Aurélien Pommier, C. Hotz
Pharmacological Research (2019) Vol. 154, pp. 104192-104192
Open Access | Times Cited: 57
Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade
Yu-Chen Chuang, Jen-Chih Tseng, Li-Rung Huang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 54
Modified internucleoside linkages for nuclease-resistant oligonucleotides
Guillaume Clavé, Maëva Reverte, Jean‐Jacques Vasseur, et al.
RSC Chemical Biology (2020) Vol. 2, Iss. 1, pp. 94-150
Open Access | Times Cited: 50
Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients
Adèle de Masson, Delphine Darbord, Gábor Dobos, et al.
Blood (2021) Vol. 139, Iss. 12, pp. 1820-1832
Open Access | Times Cited: 50
CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
Zhongkun Zhang, Jimmy Chun‐Tien Kuo, Siyu Yao, et al.
Pharmaceutics (2021) Vol. 14, Iss. 1, pp. 73-73
Open Access | Times Cited: 46
Page 1 - Next Page

Scroll to top